Global Biodefense Market

Biodefense Market Size, Share, Growth Analysis, By Type(Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Application(Hospitals and clinics, Ambulatory Care Centers, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2213 | Region: Global | Published Date: September, 2024
Pages: 157 | Tables: 63 | Figures: 75

Biodefense Market Competitive Landscape

Competition in the biodefense industry is marked by major companies and newly emerging companies' emphasis on innovative solutions. While innovative companies introduce new technologies into the market, established companies exploit large resources and experience. Increases in public-private partnerships are presently working to strengthen research and development endeavors. Such a dynamic environment motivates continuous innovation and a run for appropriate handling of changing biological threats.

Biodefense Market Top Player’s Company Profiles

  • XOMA Corporation 
  • Altimmune Inc. 
  • Emergent Biosolutions Inc. 
  • Dynavax Technologies Corporation 
  • SIGA Technologies 
  • Elusys Therapeutics Inc. 
  • Ichor Medical Systems 
  • Dynport Vaccine Company 
  • Cleveland Biolabs 
  • Bavarian Nordic 
  • Ology Bioservices 
  • Alnylam Pharmaceuticals Inc. 
  • BioCryst Pharmaceuticals Inc. 
  • PharmAthene Inc. 
  • Profectus Biosciences Inc. 
  • NanoViricides Inc. 
  • Takeda Pharmaceutical Company Limited 
  • Sanofi Pasteur 
  • GlaxoSmithKline

Biodefense Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Biodefense Market size was valued at USD 15.22 billion in 2022 and is poised to grow from USD 15.99 billion in 2023 to USD 23.67 billion by 2031, growing at a CAGR of 5.03% during the forecast period (2024-2031).

Competition in the biodefense industry is marked by major companies and newly emerging companies' emphasis on innovative solutions. While innovative companies introduce new technologies into the market, established companies exploit large resources and experience. Increases in public-private partnerships are presently working to strengthen research and development endeavors. Such a dynamic environment motivates continuous innovation and a run for appropriate handling of changing biological threats. 'XOMA Corporation ', 'Altimmune Inc. ', 'Emergent Biosolutions Inc. ', 'Dynavax Technologies Corporation ', 'SIGA Technologies ', 'Elusys Therapeutics Inc. ', 'Ichor Medical Systems ', 'Dynport Vaccine Company ', 'Cleveland Biolabs ', 'Bavarian Nordic ', 'Ology Bioservices ', 'Alnylam Pharmaceuticals Inc. ', 'BioCryst Pharmaceuticals Inc. ', 'PharmAthene Inc. ', 'Profectus Biosciences Inc. ', 'NanoViricides Inc. ', 'Takeda Pharmaceutical Company Limited ', 'Sanofi Pasteur ', 'GlaxoSmithKline'

The federal and state government must incur huge expenses towards biodefense programs to strengthen national and public health security. This expenditure is the financing needed to develop vaccines, diagnostics, and treatments so that healthcare systems are ready for any biological threats. Governments have invested in emergency planning infrastructure and training that sketches out a climate under which innovative biodefense solutions can grow. It would eventually lead to building resistance against biological attacks or pandemics. 

Modes of Personalized Medicine: One of the major biodefense market trends is the increasing popularity for personalized medicine. It is the molding that gives shape to the development of the customized vaccines and treatments focused on specific groups of people or biological threats. This technology presents many more effective and efficient response mechanisms to infectious illness and emphasizes tailored health solutions. Experts predict that when genomics and biotechnology become advanced, they will be able to create a vaccine. That vaccine will not only be highly effective in fighting off various infections but also specifically tailor-made for the genetic makeup of different populations. 

With a commanding 86.1% biodefense market share in 2023, North America led the industry and is predicted to grow with a strong CAGR throughout the forecast period. Among the many factors constituting this superiority lies huge federal outlays for enhancing public health security and technical advancements that enhance biodefense capabilities. Furthermore, growing public knowledge about biological risks continues to fuel increasing demand for effective response and preparedness plans. Such big giants in the field offer the market a much-required boost by enforcing innovation and newer goods and services upon the earth. All these contribute to reifying North America as the global leader in the biodefense industry. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biodefense Market

Report ID: SQMIG35H2213

$5,300
BUY NOW GET FREE SAMPLE